TIGIT antibody
Showing 1 - 25 of 5,496
Advanced Solid Tumor Trial in Bengbu (HB0030 injection)
Recruiting
- Advanced Solid Tumor
- HB0030 injection
-
Bengbu, Anhui, Chinathe First Affiliated Hospital of Bengbu Medical College
Jan 20, 2023
Advanced Malignancies Trial in Beijing (IBI939, IBI939+ Sintilimab)
Active, not recruiting
- Advanced Malignancies
- IBI939
- IBI939+ Sintilimab
-
Beijing, ChinaPeking University Cancer Hospital & Institute
Oct 4, 2022
Locally Advanced or Metastatic Solid Tumors, NSCLC Trial in Australia (HLX301)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- Non-small Cell Lung Cancer
-
Blacktown, New South Wales, Australia
- +4 more
May 25, 2022
Endometrial Tumors, Ovarian Cancer, Solid Tumor Trial in United States (COM701 in combination with BMS-986207 and nivolumab.)
Recruiting
- Endometrial Neoplasms
- +3 more
- COM701 in combination with BMS-986207 and nivolumab.
-
Chicago, Illinois
- +8 more
Aug 8, 2022
Advanced Tumors Trial in Guangzhou (JS006 as Monotherapy, JS006 in combination with Toripalimab)
Recruiting
- Advanced Tumors
- JS006 as Monotherapy
- JS006 in combination with Toripalimab
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Sep 21, 2021
Solid Tumor Trial in Guanzhou (BAT6021)
Recruiting
- Solid Tumor
-
Guanzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Jul 26, 2022
Esophageal Squamous Cell Carcinoma Trial in Worldwide (Tislelizumab, Ociperlimab, Placebo)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Tislelizumab
- +2 more
-
Hefei, Anhui, China
- +85 more
Aug 19, 2022
NSCLC Trial in Worldwide (Atezolizumab, Tiragolumab, Placebo)
Active, not recruiting
- Non-small Cell Lung Cancer
- Atezolizumab
- +2 more
-
Tempe, Arizona
- +40 more
Nov 11, 2022
Advanced Tumor Trial (PM1009 injection)
Not yet recruiting
- Advanced Tumor
- PM1009 injection
- (no location specified)
Nov 7, 2022
Head and Neck Tumors, MSI-H Cancer, Melanoma Trial (Tiragolumab and atezolizumab)
Not yet recruiting
- Head and Neck Neoplasms
- +2 more
- Tiragolumab and atezolizumab
- (no location specified)
Aug 1, 2022
Locally Advanced Cancer, Metastatic Cancer Trial in United States (OMP-313M32, Nivolumab)
Terminated
- Locally Advanced Cancer
- Metastatic Cancer
-
Scottsdale, Arizona
- +4 more
Aug 10, 2020
Advanced Cancer, Ovarian Cancer, Lung Cancer Trial in United States (Dose escalation: COM902 monotherapy., Evaluation of
Recruiting
- Advanced Cancer
- +6 more
- Dose escalation: COM902 monotherapy.
- +3 more
-
Grand Rapids, Michigan
- +5 more
Aug 8, 2022
Locally Advanced and Metastatic Solid Tumors Trial in Worldwide (Ociperlimab, Tislelizumab, Pemetrexed)
Recruiting
- Locally Advanced and Metastatic Solid Tumors
- Ociperlimab
- +10 more
-
Phoenix, Arizona
- +66 more
May 16, 2022
Advanced Solid Tumours Trial (PM1021, PM8001)
Not yet recruiting
- Advanced Solid Tumours
- PM1021, PM8001
- (no location specified)
Sep 12, 2022
Advanced NSCLC Trial in Spokane (Zimberelimab, Domvanalimab, Quemliclustat)
Recruiting
- Advanced Non-Small Cell Lung Cancer
- Zimberelimab
- +4 more
-
Spokane, WashingtonMedical Oncology Associates
Jan 5, 2023
Melanoma Trial in Pittsburgh (Zimberelimab, Domvanalimab)
Recruiting
- Melanoma
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Apr 11, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (GP+PD-1+Tight)
Withdrawn
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaZhongshan hospital, Fudan University
Mar 22, 2022
NSCLC Trial (Atezolizumab, Tiragolumab)
Not yet recruiting
- Non-small Cell Lung Cancer
- (no location specified)
Apr 11, 2023
Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor Trial in United Kingdom, United States (Etigilimab dosing,
Recruiting
- Solid Tumor, Adult
- +2 more
- Etigilimab dosing
- Nivolumab
-
Phoenix, Arizona
- +15 more
Jun 6, 2022
Advanced Malignant Tumors Trial (AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion)
Not yet recruiting
- Advanced Malignant Tumors
- AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion
- (no location specified)
May 11, 2023